Table 3

Frequency of the consumption of driving-impairing medicines by ATC group

ATC groupsPatients under treatment
% (95% CI)
Drivers under treatment
% (95% CI)
MalesFemalesTotalMalesFemalesTotal
A5.3 (5.26 to 5.34)5.5 (5.46 to 5.54)5.4 (5.37 to 5.43)5.13 (5.08 to 5.17)2.24 (2.21 to 2.28)3.98 (3.95 to 4.02)
C0.36 (0.35 to 0.37)0.26 (0.25 to 0.26)0.31 (0.3 to 0.31)0.32 (0.31 to 0.33)0.04 (0.04 to 0.05)0.21 (0.2 to 0.22)
D0.12 (0.12 to 0.13)0.11 (0.1 to 0.11)0.11 (0.11 to 0.12)0.07 (0.07 to 0.08)0.08 (0.07 to 0.09)0.08 (0.07 to 0.08)
G0.6 (0.59 to 0.62)1 (0.99 to 1.02)0.81 (0.79 to 0.82)0.52 (0.5 to 0.53)0.49 (0.47 to 0.51)0.51 (0.49 to 0.52)
J0.02 (0.02 to 0.03)0.03 (0.03 to 0.04)0.03 (0.03 to 0.03)0.03 (0.02 to 0.03)0.03 (0.02 to 0.03)0.03 (0.02 to 0.03)
L0.51 (0.49 to 0.52)0.07 (0.06 to 0.07)0.28 (0.28 to 0.29)0.37 (0.36 to 0.38)0.05 (0.04 to 0.05)0.24 (0.23 to 0.25)
M0.7 (0.69 to 0.72)1.11 (1.09 to 1.13)0.91 (0.9 to 0.92)0.78 (0.76 to 0.8)1.02 (0.99 to 1.04)0.87 (0.86 to 0.89)
N22.45 (22.37 to 22.52)35.68 (35.6 to 35.77)29.17 (29.12 to 29.23)21.51 (21.42 to 21.6)21.02 (20.91 to 21.12)21.31 (21.25 to 21.38)
P0.08 (0.07 to 0.08)0.24 (0.23 to 0.25)0.16 (0.15 to 0.16)0.08 (0.07 to 0.09)0.19 (0.18 to 0.2)0.12 (0.12 to 0.13)
R3.62 (3.59 to 3.65)4.38 (4.34 to 4.41)4 (3.98 to 4.03)2.51 (2.48 to 2.54)1.98 (1.94 to 2.02)2.3 (2.27 to 2.32)
S0.41 (0.4 to 0.42)0.42 (0.41 to 0.43)0.41 (0.41 to 0.42)0.33 (0.32 to 0.35)0.1 (0.09 to 0.1)0.24 (0.23 to 0.25)
V0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)
  • A, alimentary tract and metabolism; ATC, Anatomical Therapeutic Chemical Classification System; C, cardiovascular system; D, dermatologicals; G, genitourinary system and sex hormones; J, antiinfectives for systemic use; L, antineoplastic and immunomodulating agents; M, musculoskeletal system; N, nervous system; P, antiparasitic products, insecticides and repellents; R, respiratory system; S, sensory organs; V, various.